Transcenta Announces Orphan Drug Designation Granted to TST001 for Treatment of Gastric and Gastroesophageal Junction
News provided by
Share this article
Share this article
SUZHOU, China, July 28, 2021 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to TST001, its anti-Claudin18.2 monoclonal antibody currently in Phase I clinical trial, for the treatment of patients with gastric cancer or gastroesophageal junction (GC/GEJ). According to preclinical and clinical data, TST001 displayed potent anti-tumor activities in tumor model of gastric cancer or patient of gastric cancer expressing Claudin18.2.
Dairy Dialog podcast 143: Adventa Bioscience, Change Foods, Tate & Lyle dairyreporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dairyreporter.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SUZHOU, China, July 14, 2021 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a clinical stage global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announces that the first US patient has been dosed in the global Phase I clinical trial of PD-L1/TGF-β bi-functional antibody TST005.
TST005 is the second bi-functional anti-PD-L1 and TGF-β trap fusion protein entering the global clinical stage. It simultaneously targets two immuno-suppressive pathways, transforming growth factor -β (TGF-β) and programmed cell death ligand-1 (PD-L1), that are commonly used by cancer cells to evade the immune system. TST005 consists of a high affinity PD-L1 antibody fused with an engineered TGF-β Receptor Type II protein in its C-terminal. TST005 lacks FcR binding activity and thus has reduced FcR mediated killing of PD-L1 expressing effector T cells. TST005 s high
(2) DJ EQS-News: Ten Pao Group Issues 2021 Interim Results Positive Profit Alert Net Profit Attributable to Equity Holders of the Company is Expected to Increase by 90% to 110% YoY EQS-News / 13/07/2021 / 09:46 UTC+8 ?For Immediate Release? 12 July 2021 Ten Pao Group Holdings Limited ?????????? (Stock Code:1979.HK) Ten Pao Group Issues 2021 Interim Results Positive Profit Alert Net Profit Attributable to Equity Holders of the Company is Expected to Increase by 90% to 110% YoY [12 July 2021 - Hong Kong] Ten Pao Group Holdings Limited (the Company , together with its subsidiaries, the Group , stock code: 1979.HK), is pleased to announce that based on the preliminary review by the Board on the unaudited management accounts of the Group for the six months ended 30 June 2021, the net profit attributable to equity holders of the Company is expected to increase by approximately 90% to 110% as compared to the corresponding period of last year, due to the significant increase i
Transcenta Announces NMPA Acceptance of IND Application of its Anti-Sclerostin Monoclonal Antibody TST002 prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.